山東國際生物科技園

          Park Overview

          Park Overview

          Shandong International Biotechnology Park (the Park) is jointly built by Yantai High-tech Zone and Luye Investment Group Ltd. with the support from Department of Science and Technology of Shandong Province and Yantai Municiple Government. The Park adopts innovative mode of “enterprise-style management with strong governmental support”, which is a new attempt in building  innovative system.
          Located in the core area of Yantai High-tech Zone, composed of  R&D section and the living section, the Park covers an area of 1,046 mu and the gross floor area is 1,070,000 ㎡, 560,000 ㎡ of which is R&D section. Advocating the concept of healthy living technologies, the Park will establish the most optimum research environment and living conditions in international standards, and provide full services such as technologies, funds and the living conditions for the enterprises and organizations settled in the Park. The Park will make efforts towards the target of building a world-class biotechnology base.
          The Park has taken the strategic opportunities in building the Shandong Peninsula Blue Economic Zone and developing the biotechnology industry. In 2010, the Park has been selected in the “6 top 10” scientific and technological innovation project of Yantai City, and become one of the major ten parks that will be highly supported by the government in the next five years. The Park has become one of the major three “National Drug Innovation Incubator Base” of Shandong province, and the important part of “Shandong National New Drug R&D Technology Platform” and “Shandong New Drug Innovation and development center”. May 2011, the Park was selected in the first 100 strategic new emerging industrial projects of Shandong province which will get government support in terms of finance, credit, land use, etc. The Park won the Innovation Prize in the fifth China Independent Innovation Appraisal Activity. At present, the Park has taken part in 6 technological projects of city level or national level and gained the financial support of more than 10 million RMB.
          In terms of the development strategy, the Park will be specialized in the high-end industries like biopharmaceutical, marine biopharmaceutical, biological agriculture, etc. aiming at “first-class in China and advanced in the world, with centralized advantages and prominent features”; and promote the construction of modern biopharmaceutical industry system centered on the R&D and innovation, pilot test incubation, and matching services. The Park has also established Drug Safety Evaluation Center, Biotechnology Center, Analysis & Test Center, Drug Screening & Evaluation Center, and Pharmacokinetics Research Center, Marine Bio-pharmacy R&D Center, Pilot Test Base, etc.
          Since the inception of the project, it has gained positive responses from the industry both home and abroad. At present, more than 10 famous research institutes and universities have signed the admission contracts with the Park, including Institute of Shanghai Institute of Materia Medica, Tongji University, China Pharmaceutical University, Chinese Academy of Sciences; National Center for Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences; Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences; Singapore JURONG International Holdings Pte Ltd.; Modern Research Center of Traditional Chinese Medicine, Tsinghua University; Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences; Bio-resource Laboratory, Institute of Coastal Zone Research, Chinese Academy of Sciences; Tianjin Institute of Pharmaceutical Research; America Hamner Institutes for Health Sciences; Institute of Marine Biology, Far East Branch, Russian Academy of Sciences; Beijing Vigoo Biological Co Ltd. (New Vaccine National Engineering Research Center); Tongji University, Shandong University, Shanghai University of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Fudan University, Zhejiang University, as well as Venture Capitalists like Softbank China Venture Capital(SBCVC) and America Trout Capital Group LLC.
          At present, more than 20 biotechnology innovation projects have signed contracts with the Park and moved in the Park. The projects cover various biology and pharmaceutical technologies like therapeutic protein, polypeptide, monoclonal antibody, stem cells, bio diagnostic reagent, biological diagnostic reagent, biochip, biosimilar drug, marine pharmaceutical, modern Chinese medicine, medical equipment, animal vaccines and drugs, bio-breeding, etc. And the project leaders and the talents mostly have overseas education background. The introduction of the projects and the talents will greatly promote the development of the Park.
          Legal Notice | Sitemap | Feedback |
          Copyright ? Shandong International Biotechnology Park All rights reserved
          主站蜘蛛池模板: 四虎影视884a精品国产四虎| 国产伦精品一区二区免费| 久久精品国产亚洲沈樵| 亚洲中文字幕无码久久精品1| 97久视频精品视频在线老司机| 精品无码AV无码免费专区| 亚洲国产综合精品一区在线播放 | 精品久久久久香蕉网| 一本色道久久88综合日韩精品| 久久精品夜色噜噜亚洲A∨| 国产乱码精品一区二区三| 国产A√精品区二区三区四区| 狠狠色丁香婷婷综合精品视频| 在线精品亚洲一区二区小说| 精品无码一区在线观看| 亚洲精品国产精品乱码不卞| 久久精品综合一区二区三区| 国产视频精品免费视频| 国产精品无码专区在线观看| 国产精品白丝AV嫩草影院| 国产福利电影一区二区三区久久久久成人精品综合| 精品久久久久香蕉网| 国产精品无套内射迪丽热巴| 日韩精品无码免费一区二区三区 | 99久re热视频这里只有精品6| 国产精品久久久久久一区二区三区| 大伊香蕉精品一区视频在线| 国产麻豆精品一区二区三区v视界 国产麻豆一精品一AV一免费 | 久久精品国产99久久丝袜| 国产欧美日韩综合精品一区二区三区| 亚洲一二成人精品区| 91人前露出精品国产| 国产成人精品日本亚洲专区| 国产欧美精品一区二区三区四区| 国产专区日韩精品欧美色| 久久99精品久久久久久水蜜桃| 国产综合精品久久亚洲 | 香蕉依依精品视频在线播放| 夜夜精品无码一区二区三区 | 亚洲欧洲久久久精品| 一本一本久久a久久精品综合麻豆|